Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
A Phase I-II Trial of Fenretinide (4-HPR) + Rituximab in Patients With B-cell Lymphoma
Sponsor: National Cancer Institute (NCI)
Terminated
NCI stopped supplying fenretinide in November of 2012.
Other terminated trials from National Cancer Institute (NCI)
A PHASE1/PHASE2 clinical study on Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma and B-cell Chronic Lymphocytic Leukemia, this trial is terminated or withdrawn. The trial is conducted by National Cancer Institute (NCI) and has accumulated 8 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE1_PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1_PHASE2
First recorded
Oct 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .